Investigating genetic variations within a primary tumor and additional diversity found in tumor DNA in the bloodstream could help guide and improve treatment choices in patients with gastroesophageal adenocarcinoma.
A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma.
Risk algorithms for pediatric patients with acute lymphoblastic leukemia should incorporate genetics with minimal residual disease for optimal accuracy.
A recent analysis showed that aftercare strategies for soft-tissue sarcoma are misguided and are in need of time- and risk-adapted methods.
Factors predicting HER2 discordance between primary tumor and circulating tumor cells may be used as a surrogate for tumor biology and tumor heterogeneity in patients with breast cancer.
The FDA has approved an adjuvant treatment for adult patients who are at a high risk of renal cell carcinoma returning after nephrectomy.
The US Food and Drug Administration has expanded the indication for a drug to treat previously untreated follicular lymphoma.
Testing for mismatch repair deficiency remains underused among adults with colorectal cancer, despite the existence of well-established guidelines aimed at high-risk populations.
The FDA has granted breakthrough therapy designation to a CAR-T drug for the treatment of patients with relapsed or refractory multiple myeloma.
Laws designed to equalize out-of-pocket costs faced by cancer patients undergoing chemotherapy — whether treated intravenously, with pills or liquid doses — are having mixed results.